Browsing ICR Divisions by author "Kaiser, Martin"
Now showing items 61-80 of 86
-
Positive selection as the unifying force for clonal evolution in multiple myeloma.
Diamond, B; Yellapantula, V; Rustad, EH; Maclachlan, KH; Mayerhoefer, M; et al. (SPRINGERNATURE, 2021-01-22) -
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij, CPM; Broekmans, MEC; van Duin, M; Frerichs, KA; Kuiper, R; et al. (ELSEVIER, 2021-04-27)Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising ... -
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Shah, V; Sherborne, AL; Johnson, DC; Ellis, S; Price, A; et al. (SPRINGERNATURE, 2020-03-11) -
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah, V; Sherborne, AL; Walker, BA; Johnson, DC; Boyle, EM; et al. (NATURE PUBLISHING GROUP, 2018-01-01)Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) ... -
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea, C; Kyle, R; Rosiñol, L; Paiva, B; Engelhardt, M; et al. (SPRINGERNATURE, 2021-12-02)Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. ... -
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou, C; Porta, N; Sharma, B; Levine, D; Koh, D-M; et al. (RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2021-09-01)Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, ... -
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Cook, G; John Ashcroft, A; Pratt, G; Popat, R; Ramasamy, K; et al. (2020-07) -
Regions of homozygosity as risk factors for multiple myeloma.
Went, M; Sud, A; Li, N; Johnson, DC; Mitchell, JS; et al. (WILEY, 2019-07-01)Genomic regions of homozygosity (ROH), detectable in outbred populations, have been implicated as determinants of inherited risk. To examine whether ROH is associated with risk of multiple myeloma (MM), we performed ... -
Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging.
Barwick, T; Orton, M; Koh, DM; Kaiser, M; Rockall, A; et al. (BRITISH INST RADIOLOGY, 2021-04-01)OBJECTIVE: To assess intra- and inter-reader variability of apparent diffusion coefficient (ADC) and fat fraction (FF) measurement in focal myeloma bone lesions and the influence of lesion size. METHODS: 22 myeloma patients ... -
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Bird, S; Panopoulou, A; Shea, RL; Tsui, M; Saso, R; et al. (ELSEVIER SCI LTD, 2021-05-25) -
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (ELSEVIER SCI LTD, 2019-12-01)BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents ... -
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos, MA; Palumbo, A; Corradini, P; Cavo, M; Delforge, M; et al. (AMER SOC HEMATOLOGY, 2016-07-28)Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ... -
Search for multiple myeloma risk factors using Mendelian randomization.
Went, M; Cornish, AJ; Law, PJ; Kinnersley, B; van Duin, M; et al. (AMER SOC HEMATOLOGY, 2020-05-26)The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian randomization (MR) phenome-wide association study ... -
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones, JR; Cairns, DA; Gregory, WM; Collett, C; Pawlyn, C; et al. (NATURE PUBLISHING GROUP, 2016-12-09)We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary ... -
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino, M; Cairns, DA; Lahuerta, JJ; Wester, R; Bertsch, U; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-10-10)PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the ... -
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Shah, V; Johnson, DC; Sherborne, AL; Ellis, S; Aldridge, FM; et al. (AMER SOC HEMATOLOGY, 2018-12-06)Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 ... -
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Saavedra-García, P; Roman-Trufero, M; Al-Sadah, HA; Blighe, K; López-Jiménez, E; et al. (NATL ACAD SCIENCES, 2021-04-27)Cancer cells can survive chemotherapy-induced stress, but how they recover from it is not known. Using a temporal multiomics approach, we delineate the global mechanisms of proteotoxic stress resolution in multiple myeloma ... -
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Jenner, MW; Pawlyn, C; Davies, FE; Menzies, T; Hockaday, A; et al. (WILEY, 2022-12-21)Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The 'Myeloma XI' trial, ... -
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.
Parzych, K; Saavedra-García, P; Valbuena, GN; Al-Sadah, HA; Robinson, ME; et al. (NATURE PUBLISHING GROUP, 2019-04-25)VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we ... -
The genomic landscape of plasma cells in systemic light chain amyloidosis.
Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; et al. (AMER SOC HEMATOLOGY, 2018-12-27)